Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of written informed consent prior to conducting any study-related procedures, including withdrawal of medications.~2. Male subjects aged 18 to 55 years, inclusive at Screening.~3. Body mass index (BMI) calculated as weight in kg/height in m2 from ≥18 to ≤30 kg/m2 and weight ≥50 kg at Screening.~4. Healthy, free from any clinically significant disease/ conditions (including all cardiovascular conditions), as determined by medical history, physical examination, clinical laboratory testing, 12-lead ECG findings at Screening and admission to the unit.~5. Spirometry readings (FEV1 and Forced Vital Capacity \[FVC\]) to be ≥80% of predicted value calculated using Quanjer 2012 reference equations (Quanjer et al 2012) at Screening.~6. Normal blood pressure (BP) (defined as systolic BP \[SBP\] ≥90 and ≤140 mmHg, and diastolic BP \[DBP\] ≥50 and ≤90 mmHg) at Screening and admission to the unit, measured after resting in supine position for at least 10 minutes.~7. Normal heart rate (HR) (defined as HR ≥45 and ≤90) measured after resting in supine position for at least 10 minutes at Screening and admission to the unit.~8. Negative for hepatitis B surface antigen (HBsAg), hepatitis B core (HBc) antibody (IgM), hepatitis C antibody and human immunodeficiency virus (HIV) I and II antibodies at Screening.~9. Negative for drugs of abuse and alcohol tests at Screening and admission to the unit.~10. Normal serum potassium at Screening and at admission to the unit.~11. Willing and able to comply with study specific procedures and restrictions~Exclusion Criteria:~1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).~2. Surgical history clinically relevant for the purpose of the study or any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of Screening.~3. History of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localised basal cell carcinoma of the skin.~4. Current smokers, or a smoking history during the last 6 months or total smoking history of more than 10 pack-years. Use of electronic cigarettes or other forms of nicotine, current use or use within the last 6 months.~5. Prolonged QTcF interval, \>450 ms at Screening, or family history of long QT syndrome.~6. Any clinically significant arrhythmia noted on telemetry recording, prior to randomisation.~7. History of excessive use or abuse of alcohol within the past 2 years.~8. History of drug abuse within the past 2 years.~9. Donation or loss \>400 ml of blood and plasma within the previous 3 months prior to Visit 1, Screening.~10. History of presence of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity to any drug, as judged by the Investigator or history of hypersensitivity to drugs pharmacologically related to study drug.~11. PR (PQ) interval shortening \<120 ms (PR \>110 ms but \<120 ms is acceptable if there is no evidence of ventricular pre-excitation) at Screening.~12. PR (PQ) interval prolongation (\> 240 ms), intermittent second (Wenckebach block while asleep is not exclusive), or third degree atrioventricular block, or atrioventricular dissociation at Screening.~13. Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS \>110 ms.~14. Subject who does not agree to follow instructions to avoid partner pregnancy.~15. Subject who is not able to adhere to the restrictions on prior and concomitant medications.~16. Used any investigational drug within 3 months prior to Screening or within the equivalent time of 5 half-lives of receiving the last administration, whichever is longer, or on an extended follow-up after receiving an IMP.~17. Subjects unable to communicate reliably with the Investigator.~18. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1, AZD8871 300 μg or placebo (Type: EXPERIMENTAL): In Cohort 1, participants will receive a single dose of AZD8871 300 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
- Cohort 2, AZD8871 600 μg or placebo (Type: EXPERIMENTAL): In Cohort 2, participants will receive a single dose of AZD8871 600 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
- Cohort 3, AZD8871 900 μg or placebo (Type: EXPERIMENTAL): In Cohort 3, participants will receive a single dose of AZD8871 900 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete